What is the primary reason for the decline in net sales for the third quarter of 2001?

The primary reason for the decline in net sales for the third quarter of 2001 was the introduction of generic fluoxetine (Prozac) into the U.S. market in early August 2001. This led to a significant decrease in Prozac sales, which historically represented a substantial portion of the company's revenue.

How is Eli Lilly addressing the impact of generic competition for Prozac?

Eli Lilly is experiencing a significant decline in Prozac sales due to generic competition. The company is also involved in patent litigation to protect its Zyprexa patent and has a pending Supreme Court review for the Prozac patent. While the company is investing in its R&D pipeline and focusing on the growth of other key products like Zyprexa, Evista, Gemzar, and diabetes care products, the loss of Prozac exclusivity presents a near-term challenge.

What are the significant unusual items impacting the financial results in Q3 2001?

In the third quarter of 2001, Eli Lilly recorded several unusual items: a $90.5 million charge for acquired in-process technology from new collaborations, $121.4 million in asset impairments and other site charges related to manufacturing capacity assessment, and an extraordinary charge of $25.6 million ($16.6 million net of tax) from repurchasing higher-interest-rate debt.

What is the company's outlook regarding future sales and earnings?

Eli Lilly currently expects single-digit sales growth for both 2001 and 2002. Excluding unusual items, the company anticipates earnings per share to be between $2.75 to $2.77 for the full year 2001 and $2.70 to $2.80 for 2002. For 2003, the company is targeting high-teen earnings-per-share growth, excluding unusual items.

LLY 10-Q Quarterly Report Q3 FY2001 — Revenue, Net Income, EPS

Summary

Eli Lilly & Co. reported its third-quarter and nine-month results for the period ending September 30, 2001. The company experienced a notable decline in net sales for the third quarter, primarily due to the introduction of generic fluoxetine (Prozac) in the U.S. market. While overall net sales saw a modest increase for the nine-month period, adjusted for certain one-time charges and the impact of generic competition, the company demonstrated underlying growth in key products like Zyprexa, Evista, Gemzar, and its diabetes care portfolio. However, the report also highlights significant R&D investments and strategic initiatives, including new collaborations and asset impairment charges, which impacted profitability in the short term. Investors should pay close attention to the ongoing patent litigation surrounding Prozac and Zyprexa, as an unfavorable outcome could materially affect future results. The company's financial position remains solid, supported by strong operating cash flow and a substantial cash and investment balance, enabling continued investment in growth and shareholder returns through dividends and share repurchases. Despite near-term challenges from patent expirations, Lilly appears committed to its long-term growth strategy, focusing on its promising pipeline and expanding market presence for its key pharmaceutical products.

Key Highlights

1Net sales for Q3 2001 decreased by 2% to $2.87 billion, significantly impacted by the entry of generic fluoxetine (Prozac). Excluding Prozac, worldwide sales grew by 15%.
2Nine-month net sales increased by 11% to $8.71 billion. Excluding Prozac and adjusting for year-2000 related sales, growth was 17% for the nine months.
3Zyprexa sales showed strong growth, increasing 26% in Q3 to $812.5 million and 32% for the nine months to $2.19 billion, benefiting from new market launches.
4Significant R&D investment continued, with R&D expenses increasing 12% for both the quarter and the nine months, totaling $566.0 million and $1.65 billion respectively.
5The company recorded $90.5 million in acquired in-process technology charges related to new collaborations and $121.4 million in asset impairment and other site charges in Q3 2001.
6Prozac sales (including Prozac Weekly and Sarafem) decreased significantly by 34% in Q3 due to generic competition, and decreased 7% for the nine months.
7Cash and cash equivalents, along with short-term investments, totaled $3.59 billion as of September 30, 2001, providing ample liquidity.

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 2001

Summary

Key Highlights

Frequently Asked Questions